Paper · 33387490

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

O'Hara MH and 31 others. Lancet Oncol, 2021. Cited by 258 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Papers, record 33387490. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33387490

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.; PubMed
Journal: Lancet Oncol; PubMed
Year: 2021; PubMed
Publication types: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/33387490/; PubMed
DOI: https://doi.org/10.1016/s1470-2045(20)30532-5; PubMed
The journal: https://conductscience.org/library/journal-index/100957246; PubMed
Citations, by iCite: 258; iCite
Relative citation ratio, by iCite: 12.9; iCite
Revised in PubMed: 2022-12-07; PubMed

Authors32

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	O'Hara MH	Mark H
2	O'Reilly EM	Eileen M
3	Varadhachary G	Gauri
4	Wolff RA	Robert A
5	Wainberg ZA	Zev A
6	Ko AH	Andrew H
7	Fisher G	George
8	Rahma O	Osama
9	Lyman JP	Jaclyn P
10	Cabanski CR	Christopher R

1 to 10 of 32Source PubMed

See all 32 authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Adenocarcinoma	Major topic
Albumins	Major topic
Antineoplastic Combined Chemotherapy Protocols	Major topic
CD40 Antigens	Major topic
Deoxycytidine	Major topic
Nivolumab	Major topic
Paclitaxel	Major topic
Pancreatic Neoplasms	Major topic
Aged
Female
Humans
Male
Middle Aged
Time Factors
Treatment Outcome
United States
Gemcitabine

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
			P30CA008748	NIH

Source NIH RePORTER

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	Derived from the trial	Yes	ClinicalTrials.gov
NCT04787991	Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	Background		ClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Comment in	33,387,488	APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma.	https://conductscience.org/library/papers/33387488

Source PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by197

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 258 citations.

PMID	Title	Journal	Year	In Papers	Source
42,909,037	Myeloid-driven immunosuppression as a context-dependent therapeutic bottleneck in pancreatic ductal adenocarcinoma.	Front Immunol	2026	https://conductscience.org/library/papers/42909037	PubMed
42,794,986	Combination Immunotherapy in Pancreatic Cancer: Current Clinical Evidence and Mechanistic Rationale for Overcoming a "Cold" Tumor.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42794986	PubMed
42,723,988	Agonistic anti-CD40 antibodies in patients with solid tumors: a systematic review and evidence map of clinical safety, with exploratory proportional synthesis.	Front Immunol	2026	https://conductscience.org/library/papers/42723988	PubMed
42,667,071	Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies.	Ann Pancreat Cancer	2026	https://conductscience.org/library/papers/42667071	PubMed
42,654,051	Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling.	Pharmaceutics	2026	https://conductscience.org/library/papers/42654051	PubMed
42,513,436	Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.	J Clin Med	2026	https://conductscience.org/library/papers/42513436	PubMed
42,279,326	CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42279326	PubMed
42,212,312	Targeting Tumor-Associated Macrophages to Reshape the Immuno-Mechanical Landscape: Molecular Mechanisms and Therapeutic Strategies.	Int J Biol Sci	2026	https://conductscience.org/library/papers/42212312	PubMed
42,196,390	Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42196390	PubMed
42,156,568	Realizing the potential of agonistic antibody immunotherapy.	Nat Rev Drug Discov	2026	https://conductscience.org/library/papers/42156568	PubMed

1 to 10 of 197

See all 197 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
CD40	958	PubTator's text mining	https://conductscience.org/library/genes/958

Source NCBI Gene

Drugs4

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
NIVOLUMAB	CHEMBL2108738	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL2108738	ChEMBL
PACLITAXEL	CHEMBL428647	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL428647	ChEMBL
SOTIGALIMAB	CHEMBL4297888	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL4297888	ChEMBL
GEMCITABINE	CHEMBL888	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL888	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33387490

GET https://conductscience.org/api/papers/v1/33387490/authors?page=2

API reference For AI assistants